| Online-Ressource |
Verfasst von: | Weykamp, Fabian [VerfasserIn] |
| Herder-Wagner, Charlotte [VerfasserIn] |
| Regnery, Sebastian [VerfasserIn] |
| Hoegen, Philipp [VerfasserIn] |
| Renkamp, Claudia Katharina [VerfasserIn] |
| Liermann, Jakob [VerfasserIn] |
| Rippke, Carolin [VerfasserIn] |
| Körber, Stefan A. [VerfasserIn] |
| König, Laila [VerfasserIn] |
| Buchele, Carolin [VerfasserIn] |
| Klüter, Sebastian [VerfasserIn] |
| Debus, Jürgen [VerfasserIn] |
| Hörner-Rieber, Juliane [VerfasserIn] |
Titel: | Stereotactic body radiotherapy of lymph node metastases under MR-guidance |
Titelzusatz: | First clinical results and patient-reported outcomes |
Verf.angabe: | Fabian Weykamp, Charlotte Herder-Wagner, Sebastian Regnery, Philipp Hoegen, C. Katharina Renkamp, Jakob Liermann, Carolin Rippke, Stefan A. Koerber, Laila König, Carolin Buchele, Sebastian Klüter, Jürgen Debus, Juliane Hörner-Rieber |
Jahr: | 2022 |
Umfang: | 10 S. |
Fussnoten: | Online veröffentlicht: 1 September 2021 ; Gesehen am 21.08.2023 |
Titel Quelle: | Enthalten in: Strahlentherapie und Onkologie |
Ort Quelle: | Berlin : Springer Medizin, 1997 |
Jahr Quelle: | 2022 |
Band/Heft Quelle: | 198(2022), 1, Seite 56-65 |
ISSN Quelle: | 1439-099X |
Abstract: | Objective Stereotactic body radiotherapy (SBRT) is a noninvasive treatment option for lymph node metastases (LNM). Magnetic resonance (MR)-guidance offers superior tissue contrast and enables treatment of targets in close vicinity to radiosensitive organs at risk (OAR). However, literature on MR-guided SBRT of LNM is scarce with no report on outcome parameters. Materials and methods We report a subgroup analysis of a prospective observational study comprising patients with LNM. Patients received MR-guided SBRT at our MRIdian Linac (ViewRay Inc., Mountain View, CA, USA) between January 2019 and February 2020. Local control (LC), progression-free survival (PFS) and overall survival (OS) analysis were performed using the Kaplan-Meier method with log rank test to test for significance (p < 0.05). Our patient-reported outcome questionnaire was utilized to evaluate patients’ perspective. The CTCAE (Common Terminology Criteria for Adverse Events) v. 5.0 was used to describe toxicity. - Results Twenty-nine patients (72.4% with prostate cancer; 51.7% with no distant metastases) received MR-guided SBRT for in total 39 LNM. Median dose was 27 Gy in three fractions, prescribed to the 80% isodose. At 1-year, estimated LC, PFS and OS were 92.6, 67.4 and 100.0%. Compared to baseline, six patients (20.7%) developed new grade I toxicities (mainly fatigue). One grade II toxicity occurred (fatigue), with no adverse event grade ≥III. Overall treatment experience was rated particularly positive, while the technically required low room temperature still represents the greatest obstacle in the pursuit of the ideal patient acceptance. - Conclusion MR-guided SBRT of LNM was demonstrated to be a well-accepted treatment modality with excellent preliminary results. Future studies should evaluate the clinical superiority to conventional SBRT. |
DOI: | doi:10.1007/s00066-021-01834-w |
URL: | kostenfrei: Volltext: https://doi.org/10.1007/s00066-021-01834-w |
| kostenfrei: Volltext: https://link.springer.com/10.1007/s00066-021-01834-w |
| DOI: https://doi.org/10.1007/s00066-021-01834-w |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 1856812537 |
Verknüpfungen: | → Zeitschrift |
|
|
| |
Lokale URL UB: | Zum Volltext |
Stereotactic body radiotherapy of lymph node metastases under MR-guidance / Weykamp, Fabian [VerfasserIn]; 2022 (Online-Ressource)